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Mupirocin is a bacteriostatic antibiotic that is used to decolonize people who 
carry methicillin-resistant staphylococci, primarily methicillin-resistant Staphylococcus 
aureus (MRSA).  Mupirocin reversibly binds to bacterial isoleucyl tRNA synthetase to 
disrupt protein synthesis.  Resistance to mupirocin is due either to a point mutation to the 
ileS gene that encodes the isoleucyl tRNA synthetase, classified as low-level mupirocin 
resistance; or, bacteria may obtain a plasmid that carries the ileS2 gene encoding an 
alternate isoleucyl tRNA synthetase, conferring high-level resistance.  Mupirocin 
resistance plasmids contain insertion sequence (IS) 257 repeats, into which the ileS2 
gene is inserted.  Such plasmids have been characterized by their IS257-ileS2 junctions 
in both S. aureus and, recently, in Staphylococcus pseudintermedius in a dog from 
Croatia.  The primary goals of this study were to determine the prevalence of mupirocin 
resistance in isolates of S. pseudintermedius in Texas, to determine whether resistance 
was due to point mutations in the native ileS or due to carriage of mupirocin resistance 
plasmids, and to characterize the structure of the mupirocin resistance genes carried on 
plasmids. 
In this study, 572 S. pseudintermedius isolates, collected from veterinary patients 
from across Texas were screened for their susceptibility to low levels of mupirocin.  Of 
these isolates, only one out of 572 (0.17%) tested positive for mupirocin resistance and 
was found by polymerase chain reaction (PCR), using previously published primers 
mupA and mupB, to have a 458 bp fragment and, with primers M1 and M2 to have a 
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237 bp fragment, indicating the presence of the high-level mupirocin resistance gene, 
ileS2.  The arrangement of the IS257-ileS2 junctions was then analyzed by PCR and the 
products, bands at 1816 bp for primers ileS2-5’ and IS257R and at 1127 bp for primers 
ileS2-3’ and IS257F, which are consistent with the amplification pattern for an S2 
plasmid, were cloned into a plasmid, pT7Blue, and sequenced for comparison to 
published sequences in GenBank.  BLAST analyses in NCBI, comparing the isolate to 
recently published sequences for mupirocin-resistant S. pseudintermedius isolated from a 
dog with pyoderma in Croatia, indicate a 100% similarity to the upstream junction, 
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CHAPTER I  




 Staphylococci include a clinically important group of potentially pathogenic 
Gram-positive bacteria affecting both humans and animals.  The most well known 
species is Staphylococcus aureus, which  is renowned as an opportunistic pathogen 
capable of causing illnesses ranging from minor skin infections to life-threatening 
conditions, like toxic shock syndrome and endocarditis (12).  S. aureus has reached the 
attention of the public eye because it is the most common cause of hospital acquired 
infection and often carries resistance to multiple antibiotics, making it difficult to treat.  
However, other staphylococci share some of the same attributes that make S. aureus 
successful as a pathogen.  For example, Staphlylococcus pseudintermedius is capable of 
producing some of the virulence factors such as coagulase, thermonuclease, proteases, 
leukocidin, hemolysins, exfoliative toxins, enterotoxins, and pyrogenic toxin 
superantigens (14, 18).  Likewise, S. pseudintermedius can also carry some of the same 
antibiotic resistance genes and can produce biofilms (14).  In contrast, staphylococci 
differ in the surface proteins that interact with the host, causing species variation from 
host to host, with some species showing higher degrees of host specificity than others.  
To illustrate, S. aureus is the predominant staphylococcal species in humans, horses, and 
ruminants, S. pseudintermedius is the prevalent species in dogs, and Staphylococcus 
intermedius predominates in pigeons (40).  However, S. aureus is highly adaptable, 
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colonizing a variety of mammals, reptiles, and birds, and has been documented in dogs, 
cats, pigs, ruminants, horses, rabbits, and poultry (14).  Overall, Staphylococcus is a 
genus that includes successful opportunistic pathogens affecting humans and animals. 
 One clinically relevant group of staphylococci is the Staphylococcus intermedius 
group (SIG), which is known to cause infections in animals and occasionally in humans.  
Historically, S. intermedius was identified as the causative agent of pyoderma in dogs and 
had been isolated from dogs, cats, pigeons, mink, and horses (39).  Recent investigations 
into the genetics of S. intermedius revealed that rather than a single species, there was a 
cluster of closely related species which became known as the SIG (48).  This group was 
delineated after the recognition of S. pseudintermedius in 2005 (10) and subsequent 
investigations into molecular typing methods (48).  Isolates that had previously been 
phenotyped as S. intermedius were then reclassified into the SIG, which is comprised of 
S. intermedius, S. pseudintermedius, and Staphylococcus delphini (8, 48).  Sasaki et al. 
demonstrated that S. intermedius could be distinguished from S. pseudintermedius and S. 
delphini biochemically (39).  Later, Bannoehr and colleagues were able to differentiate S. 
pseudintermedius from S. delphini using polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP) (4).  Due to the discovery of S. pseudintermedius and 
advancements in genetic testing it was discovered that S. pseudintermedius, and not S. 
intermedius, was the major pathogenic species in dogs and cats (48).  Thus, it has been 
proposed that isolates previously identified as S. intermedius from dogs, be considered S. 
pseudintermedius unless genetically proven to be another member of the SIG (48).  There 
is still debate over the primary staphylococci in cats though, as evidence is present for 
both S. aureus and S. pseudintermedius (6).  Identification of bacteria in clinical 
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microbiology laboratories was originally based on Gram-stain reaction and reaction to 
biochemical tests.  One of the most important tests used for identification of 
staphylococci was their ability to initiate plasma clots through activity of the enzyme 
coagulase.  Both S. pseudintermedius and S. aureus produce coagulase.  Because 
differentiation between members of the SIG by phenotypic tests is limited, accurate 
commercial tests for identification of S. pseudintermedius are not available, and S. 
pseudintermedius is a relatively new species, it is commonly misidentified as S. 
intermedius or S. aureus; therefore, occurrence of S. pseudintermedius is likely 
underestimated in human infections (48, 50).  However, if the protocol of a veterinary 
laboratory is to presume that coagulase-positive staphylococcal isolates cultured from 
dog and cat infections are S. pseudintermedius, then it is equally likely that the incidence 
of S. pseudintermedius will be overestimated due to misidentification of S. aureus or S. 
intermedius as such.  Therefore, in assessing the occurrence of S. pseudintermedius, 
laboratory capabilities and protocols must be taken into consideration. 
 It remains common in veterinary labs to identify staphylococci based on their 
ability to produce coagulase.  S. aureus, S. intermedius, S. delphini, S. pseudintermedius, 
and Staphylococcus schleiferi subspecies coagulans are all coagulase-positive (39).  
Staphylococci that do not produce this enzyme are termed coagulase-negative 
staphylococci (CoNS).  Members of the CoNS include Staphylococcus epidermidis, the 
most common Staphylococcus found on human skin, Staphylococcus haemolyticus, and 
Staphylococcus saprophyticus, to name a few (37).  Until recently, the CoNS were 
thought to be innocuous.  However, S. epidermidis is now believed to cause most cases of 
device-related infection in hospitals, S. haemolyticus is known to cause septicemia, 
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endocarditis, and other infections, and S. saprophyticus has been found to be the second 
most common cause of urinary tract infections in women of child-bearing age (37). S. 
epidermidis is the best studied of the CoNS.  The characteristics that make S. epidermidis 
of clinical concern are its ability to form biofilms in medical devices and its ability to 
harbor antimicrobial resistance determinants (37).  The more research is done on 





S. pseudintermedius in dogs is somewhat analogous to S. aureus in humans.  Both 
organisms are commensal, living on the skin and/or mucous membranes of their 
respective hosts, and both are capable of causing infection when the epithelium is 
disrupted or during times of weakened immune response.  Of the staphylococci, S. aureus 
is considered the most significant human pathogen; notably it is a common cause of 
minor skin infections and can penetrate the epithelium at surgical incisions, intravenous 
catheter sites, and injection sites (12).  Likewise, S. pseudintermedius is the major 
pathogenic species isolated in canine pyoderma, ear infections, and is also capable of 
causing post-surgical infections (14, 16, 48).  Both organisms are also capable of 
transmission from humans to animals and vice versa. S. aureus has a wide range of host 
species, but S. pseudintermedius is typically associated with dogs.  However, S. 
pseudintermedius does have zoonotic potential, reportedly causing human infections in 
dog bite wounds (43), sinusitis (23, 42), bacteremia (7), and pneumonia (17).  Humans 
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can also be nasal carriers of S. pseudintermedius, although it is not as common.  In a 
study of dogs with deep pyoderma, it was found that dog owners frequently carried the 
same strain of S. pseudintermedius as their dog, but that this colonization was only 
transient as owners were no longer culture-positive after the dog’s infection resolved 
(19).  Veterinary dermatologists and small animal clinical staff are also nasal carriers of 
S. pseudintermedius (31). 
Both S. aureus and S. pseudintermedius are capable of causing nosocomial and 
community-acquired infections in their respective normal host species.  According to 
Lindsay, S. aureus is the most common cause of hospital acquired infection and the 
incidence of community acquired S. aureus is increasing (27).  One of the greatest 
complications of S. aureus and S. pseudintermedius infection is drug resistance, 
specifically methicillin-resistance.  Although these methicillin-resistant staphylococci are 
no more virulent than non-resistant strains, they are more difficult to treat clinically and 
can therefore spread more readily in hospitals or in community settings where people are 
in close contact with one another (27).  Zubeir et al. demonstrated by pulse field gel 
electrophoresis (PFGE) using ApaI and SmaI restriction enzymes that ten isolates of 
methicillin-resistant S. pseudintermedius (MRSP) taken from animals at a veterinary 
clinic were indistinguishable, suggesting that a single bacterial clone was distributed 
among these animals either from the clinic or in the pet population (54).  Additionally, 
both S. aureus and S. pseudintermedius are capable of acquiring multiple antimicrobial 
resistance determinants, making them difficult to treat.  This, compounded with the fact 
that staphylococci are capable of transferring resistance determinants between species, 
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means that  S. pseudintermedius in animals could serve as a reservoir for antimicrobial 
resistance for S. aureus in humans and vice versa.  
 
 History of Drug Resistance in Staphylococci 
 
Shortly after the introduction of the antibiotic penicillin in the 1940s, penicillin-
resistant staphylococci were recognized (29).  It was discovered that these S. aureus 
strains possessed the blaZ gene encoding the enzyme β-lactamase, which hydrolyzes the 
β-lactam ring of penicillin, rendering it inactive (29).  In 1961, the first semisynthetic 
penicillinase-resistant penicillin, methicillin, was introduced; shortly thereafter, 
methicillin-resistant staphylococci emerged as well (29).  Resistance to β-lactam 
antibiotics, including penicillin, methicillin, and cephalosporins, in staphylococci is 
conferred by the mecA gene which encodes the penicillin-binding protein, PBP2a (1).  
Penicillin-binding proteins catalyze transpeptidation, necessary for cross-linkage of 
peptidoglycan chains during cell wall synthesis in Gram-positive bacteria; importantly, 
PBP2a has  a low affinity for β-lactam antibiotics, enabling cell wall synthesis to 
continue even in high concentrations of such antimicrobials (29).  Staphylococci carrying 
the mecA gene are termed methicillin-resistant.  β-lactam antimicrobials are often used 
empirically and are considered first-line of defense treatment for staphylococcal 
infections in people and pyoderma in dogs because they have a low risk of adverse 
effects and good tissue penetration.  In general, this practice is effective and these drugs 
generally eliminate methicillin-susceptible staphylococci; unfortunately though, 
extensive use of β-lactam antibiotics can select for methicillin-resistant strains (6).  In 
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recent years, both methicillin-resistant S. aureus (MRSA) infections and methicillin-
resistant S. pseudintermedius (MRSP) infections have increased (14).  The incidences of 
both hospital-associated MRSA and community-acquired MRSA are increasing; 
additionally, statistics show that  20–25 percent of healthy humans carry S. aureus all the 
time and 55–60 percent carry S. aureus intermittently (12).  In healthy dogs, MRSP 
carriage can be as high as 6.2% (16/258) (31).  Historically, MRSP isolates remained 
susceptible to one or more antimicrobials outside of the β-lactam antibiotics.  Among the 
drugs alternatively selected to treat MRSP infections are fluoroquinolones, macrolides, 
lincosamides, chloramphenicol, aminoglycosides, and rifampin.  Unfortunately, 
resistance to each of these classes of antimicrobial drugs in staphylococci has increased 
in recent years and there are few choices for systemic therapy for MRSP infections (36). 
 
Staphylococcal Cassette Chromosome mec (SCCmec)  
 
Characterization of MRSP is done by sequence type determination and by typing 
the mobile element carrying the mecA gene that confers β-lactam antimicrobial 
resistance.  The mecA gene is carried on the mobile genetic element, staphylococcal 
cassette chromosome mec (SCCmec).  SCC elements carry ccr genes which encode the 
enzymes necessary for excision and integration of the element into the orfX gene of the 
staphylococcal chromosome (26).  SCCmec, has been categorized into eight different 
types, SCCmec types I – VIII, in S. aureus (47).  In S. pseudintermedius, SCCmec types 
II-III, III, IV, V, and VII and some non-typable cassettes have been observed (48), of 
which, SCCmec II-III, SCCmec V, and SCCmec VII-241 have been sequenced (36).  
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Interestingly, SCCmec II-III  contains elements of the SCCmec II from S. epidermidis 
and SCCmec III from S. aureus (36).  SCCmec typing, along with sequence typing, 
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP), 
multilocus sequence typing (MLST) and staphylococcal protein A or spa typing, can be 
used to differentiate strains of S. pseudintermedius and are used for epidemiological 
surveillance (48).  As in MRSA, different strains of MRSP predominate in North 
America than in Europe (48).  There is less genetic variability in MRSP than there is in 
methicillin-susceptible S. pseudintermedius which suggests clonal spread of specific 
genetic types of MRSP.  In European MRSP, MLST ST71-spa t02-SCCmec II-III 
predominates, whereas, in North America, MLST ST 68-spa t06- SCCmec type V 
predominates (48).  This being said, there has been evidence of worldwide dissemination 
of certain MRSP clones (48).  
 
Zoonotic Potential of Staphylococcus pseudintermedius 
 
Both healthy animals and people are capable of carrying MRSA or MRSP and 
may then serve as a reservoir for further dissemination.  However, in the context of 
veterinary medicine, MRSA strains that infect household pets are thought to be of human 
origin; whereas, MRSP strains are thought to originate from an animal reservoir (48, 50).  
Humans are not normally carriers of S. pseudintermedius; however, humans in close 
contact with animals such as dog owners or people in the veterinary profession are at 
increased risk for colonization or infection with MRSP (41).  As mentioned previously, S. 
pseudintermedius can occasionally infect humans, but just as concerning, it can 
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sometimes colonize humans as well.  In a study by van Duijkeren et al., animals in 
contact with a MRSP-infected animal were also frequently culture-positive; whereas, 
humans living in the household or working in the veterinary clinic where those animals 
were treated were positive less frequently (49).  Similarly, in their longitudinal study of 
MRSP, Laarhoven et al. discovered that in addition to the animal infected with MRSP, 
contact animals, owners, and the environment, both where the infected animal had access 
and where it did not have access, all were capable of producing positive swabs for MRSP 
in some of the households (24).  In the same study, it was shown that animals infected 
with MRSP were capable of both long-term colonization (during the entire six month 
study, with one dog also having a positive sample one year after the initial sample) and 
intermittent colonization with up to three months between positive samples (24).  In a 
similar study by Windahl et al., 61% of dogs were MRSP-positive for at least 8 months, 
although they did not test household contacts and could not rule out the possibility of 
reinfection from such sources (51).  Carriage of MRSP in animals and humans could 
potentially lead to transfer of antimicrobial resistance from the transient colonizer to the 
normal host commensal bacteria.  De Lucia et al. reported the prevalence of MRSP 
among SIG isolates over a 2 month period at a referral veterinary lab in Italy to be 21%, 
much higher than the 7.4% previously reported for dogs in Germany (8).  Combining 
these data with the fact that staphylococci are able to transfer drug resistance elements 
between each other raises great concern.  With increasing resistance to multiple classes of 
antimicrobial drugs in both S. aureus (26) and S. pseudintermedius (14, 36, 48, 50), 






 Mupirocin is a bacteriostatic antimicrobial that reversibly binds bacterial isoleucyl 
tRNA synthetase, thereby preventing protein synthesis in most Gram-positive and some 
Gram-negative bacteria.  The naturally occurring form of mupirocin, pseudomonic acid 
A, is produced by Pseudomonas fluorescens and is inhibitory to Gram-positive bacteria 
and the Gram-negative bacteria Neisseria gonorrhoeae and Haemophilus influenzae (2, 
15).  Mupirocin has a high affinity for protein binding and has a distinct reduction in 
antimicrobial activity  in the presence of serum and is therefore limited to topical use 
clinically (15).  Mupirocin, with minimum inhibitory concentrations (MICs) for most 
bacteria between 0.01 to 0.05 µg/ml, is most notable for its efficacy in elimination of 
both methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. 
aureus (MRSA) in nasal carriers in hospital settings (2).  This is its primary clinical use 
in humans.  Mupirocin has also been approved by the U.S. Food and Drug 
Administration for use as a topical antimicrobial in dogs with pyoderma.  The most 
common veterinary use of mupirocin is for topical therapy of MRSP associated with 
canine pyoderma or skin wounds.  It is notable that antimicrobial use has not been proven 
to be effective in decolonizing animals carrying MRSP (48).  The use of mupirocin to 









Two levels of mupirocin resistance occur in staphylococci: Low-level resistance 
and high-level resistance.  Low-level mupirocin resistance (MIC between 8 µg/mL and 
256 µg/mL) arises due to point mutations to the chromosomal ileS gene, which encodes 
the native isoleucyl tRNA synthetase (25).  Conversely, high-level mupirocin resistance 
(MIC   512 µg/mL) occurs through the acquisition of the plasmid-borne ileS2 gene, 
which encodes an alternate synthetase to which mupirocin does not bind (25); although, a 
chromosomal location of ileS2 has been previously reported (38).  Pseudomonas 
aeruginosa has also been found to be resistant to mupirocin (MIC > 1,024 µg/mL) (22).  
Caffrey et al. conducted a study in 2010 to identify risk factors associated with the 
development of mupirocin resistance in S. aureus; subsequently, they found that infection 
with mupirocin-resistant MRSA was more common in patients who had undergone 
surgical procedures, had chronic skin ulcers or had been infected with P. aeruginosa 
during the year prior to culture than in patients infected with mupirocin-susceptible S. 
aureus (5).  Because antimicrobial use increases the risk for selection of resistant 
bacteria, antibiotic therapy should be thoroughly considered prior to use.  Summarizing 
the principles of the European Wound Management Association’s document on the 
management of human wound infections, the goals in wound management are to 
optimize environmental factors to promote wound healing, to only use antibiotics when 
specifically indicated, and to choose antimicrobial therapies accordingly, to reduce the 




Mupirocin Resistance in Staphylococcus pseudintermedius 
 
 Mupirocin has been used on only a limited basis in veterinary medicine, primarily 
to treat pyoderma in dogs (9).  S. pseudintermedius is a common cause of skin infections, 
otitis externa, and post-operative infections in dogs.  As in S. aureus, multi-drug 
resistance is emerging in S. pseudintermedius, and, methicillin-resistant S. 
pseudintermedius (MRSP) is an increasing problem (48).  In a study conducted by Penna 
and colleagues in Brazil, 37.1% of S. pseudintermedius isolates cultured from cases of 
otitis externa in dogs were resistant to mupirocin (34).  Furthermore, Hurdle et al. 
discovered that mupirocin resistance could be passed from S. epidermidis and MRSA to 
S. aureus RN2677 in vivo (20).  It has also been found that mupirocin and tetracycline 
resistance have been conferred by the same plasmid in S. aureus (33).  Because 
staphylococci are capable of transferring plasmids between species, it is conceivable that 
S. pseudintermedius possessing plasmids carrying a mupirocin resistance gene may be 
able to transfer the plasmid or resistance gene to S. aureus in human carriers.  This could 
have significant consequences for patients colonized with MRSA or patients with wounds 
caused by MRSA for which mupirocin ointment would be a potential therapy. 
 
Mupirocin Resistance Plasmids 
 
Mupirocin resistance plasmids appear to be a modified pG01 plasmid, a well-
described conjugative plasmid in staphylococci that carries resistance genes for resistance 
to aminoglycosides, trimethoprim, and quaternary ammonium compounds (32).  Plasmid 
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pG01 can be transferred from one species of Staphylococcus to another and contains nine 
copies of an insertion sequence (IS)-like element, IS431-IS257, of which eight are 
directly repeated (32).  From their data, Morton et al. proposed the manner by which 
mupirocin resistance plasmids have evolved.  They concluded that the smallest mupirocin 
resistance plasmid, pG0400, was created via recombination of the intervening DNA 
between the IS repeats on pG01; whereby, alternate antimicrobial resistance genes and an 
integrated copy of a smaller plasmid, pUB110, were deleted when the mupirocin 
resistance gene was integrated into the IS elements (32).  Additionally, Udo et al. 
experimentally demonstrated that mupirocin-resistant conjugative plasmids are able to 
mobilize non-conjugative plasmids, similar to staphylococcal gentamicin resistance 
plasmids (45). 
Based on the premise that mupirocin resistance plasmids have a pSK41/pGO1 
backbone with the ileS2 gene inserted within the IS257 repeats, Perez-Roth et al. created 
a novel system for classifying plasmids according to the PCR amplification pattern of 
their IS257-ileS2 junctions that categorized plasmids into 15 structural groups (35).  
Perez-Roth et al. concluded that using this method, combined with molecular typing 
techniques, future spread of mupirocin resistance could be monitored and controlled more 
efficiently (35).  Recently ileS2 plasmid-mediated mupirocin resistance was found in a 
mupirocin-resistant, methicillin-susceptible S. pseudintermedius isolate in Croatia (30).  
Using the same PCR amplification methods, Matanovic and colleagues sequenced the 
IS257-ileS2 junctions of that S. pseudintermedius mupirocin resistance plasmid and 






 In summary, S. pseudintermedius is the primary pathogenic staphylococci in dogs 
and can be associated with infections in cats.  Because mupirocin is used in elimination 
of human carriage of MRSA and for treatment of canine pyoderma, mupirocin resistance 
is of great concern.  The primary goals of this study were to determine the prevalence of 
mupirocin resistance in S. pseudintermedius isolates from dogs in Texas, to classify the 
level mupirocin resistance, and to assess the molecular structure of the mupirocin 





CHAPTER II  
PRESENT STUDY 
 
Synopsis   
 
Use of mupirocin in veterinary medicine is primarily limited to the treatment of 
canine pyoderma caused by methicillin-resistant S. pseudintermedius (MRSP).  Only one 
isolate of 572 S. pseudintermedius isolates tested was resistant to mupirocin and carried 




 Staphylococcus pseudintermedius is the primary bacterial pathogen isolated from 
canine skin lesions, such as those found in pyoderma, and also causes post-surgical 
infections in dogs (14, 16).  Methicillin resistance and multi-drug resistance are 
increasing in S. pseudintermedius thus limiting the options for therapeutic treatment of 
canine skin infections (48).  Mupirocin is a bacteriostatic antibiotic that reversibly binds 
to isoleucyl tRNA synthetase to disrupt protein synthesis and is widely used to eliminate 
nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) in human MRSA 
carriers.  Mupirocin has a high affinity for protein binding and has a reduced 
effectiveness in human serum; therefore, mupirocin is only approved for topical use (2).  
Mupirocin has been used on only a limited basis in veterinary medicine, primarily to treat 
pyoderma in dogs caused by methicillin-resistant S. pseudintermedius (MRSP) (9).   
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In S. aureus, two levels of mupirocin resistance have been identified. Low-level 
mupirocin resistance occurs due to a point mutation to the chromosomal ileS gene that 
encodes the native isoleucyl-tRNA synthetase and the minimum inhibitory concentration 
(MIC) for mupirocin for staphylococci carrying the low-level resistance ranges from       
8 µg/mL to 256 µg/mL.  Conversely, high-level resistance (MIC   512 µg/mL) is usually 
conferred by the plasmid-borne ileS2, although a chromosomal location of ileS2 has been 
reported (38).  Recently, ileS2 plasmid-mediated mupirocin resistance was found in a 
mupirocin-resistant, methicillin-susceptible S. pseudintermedius isolate in Croatia (30).  
The goal of the present study was to determine the prevalence of mupirocin resistance in 
S. pseudintermedius isolates in Texas and to characterize the genes involved.   
 
Materials and Methods 
 
 In this study, 572 isolates of S. pseudintermedius were screened for phenotypic 
low-level mupirocin resistance.  Isolates were collected from veterinary patients, 
predominantly dogs (n = 447), but also included isolates from cats (n = 9).  Some animals 
were cultured multiple times in the course of their treatment or were cultured at multiple 
sites (e.g. nares and perineum).  Sources of isolates included a historical collection of 202 
isolates from 159 clinical canine infections and 6 feline infections, and contained both 
MRSP (n = 75) and methicillin-susceptible S. pseudintermedius (MSSP) (n = 127).  An 
additional 195 isolates of MRSP (n = 58) and MSSP (n = 137) were collected from 162 
clinical canine and 3 feline infections between September 22, 2010 and February 8, 2012 
concurrent with a study of MRSP prevalence in patients without clinical staphylococcal 
 17 
 
infection that presented for elective orthopedic procedures.  The prevalence study yielded 
175 isolates of MRSP (n = 13) and MSSP (n = 162) collected from the nares or perineum 
of 126 dogs (Table 1).  The isolates from clinical infections were collected from the 
following anatomic sites skin (n = 95), external ear canal (n = 40), wounds (n = 53), post-
operative infections (n = 42), and urine/urinary tract (n = 88), respiratory tract (n = 16), 
reproductive tract (n = 9) and other sources (n = 54) (Table 2).   
All isolates were presumptively identified as S. pseudintermedius at the time of 
collection by Gram-stain reaction, colony color, and biochemical tests including the 
ability to produce hemolysis on trypticase soy agar supplemented with 5% sheep blood 
agar (BD Diagnostic Systems, USA), to produce coagulase, to produce catalase, and to 
grow on salt-mannitol agar and based on their susceptibility to polymyxin B.  At the time 
of initial collection, isolates were tested for antimicrobial susceptibility using 
commercially available systems (GPS card, VITEK, bioMérieux, France; COMPAN1F 
and COMPAN2F panels, TREK Sensititre, TREK Diagnostics, USA) and tested for 
methicillin resistance by oxacillin disk diffusion testing and polymerase chain reaction 
for the presence of mecA.  Isolates were frozen in 10% glycerol at -80°C in 96-well deep 
well plates and later inoculated aseptically using a 96-pin replicator onto BBL TSA II 5% 
sheep’s blood agar plates as a control and onto Mueller-Hinton (MH) agar (BD 
Diagnostic Systems) supplemented with 8 µg/ml mupirocin (Sigma-Aldrich; USA) agar 
plate (mupirocin plate hereafter) to screen for low-level resistance to mupirocin. 
Pseudomonas aeruginosa (ATCC 27853) was used as a positive control for mupirocin 
resistance as it was shown to be mupirocin resistant (22).  Plates were incubated for 24 
hours at 37°C.  
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Plasmid purification was accomplished using the QIAprep Mini Spin kit plasmid 
purification kit (QIAgen, Valencia, CA).  The mupirocin-resistant colony was struck onto 
a mupirocin plate and incubated overnight at 37°C. A single colony was then aseptically 
transferred to 5 ml of Luria-Bertani broth (LB) and incubated on a C24 Innova shaking 
incubator (New Brunswick, USA) at 220 RPM at 37°C for 15 hours.  Using 2 aliquots of 
2 ml of sample each, the manufacturer’s instructions were followed, combining the 
aliquots during resuspension of the pellets of cells.  In the final step, DNA was eluted 
using nuclease-free water.  Samples were then tested for concentration and quality using 
a NanoDrop® spectrometer (Thermo Scientific, USA) prior to downstream reactions. 
 To perform polymerase chain reaction (PCR) for identification of the high-level 
resistance gene ileS2, the previously published primers mupA and mupB (2)  and  
primers M1 and M2 (25) were used to amplify 458 bp and 237 bp fragments, 
respectively, of the ileS2 gene (Table 3).  A total reaction volume of 50 µl was 
established for each set of primers as a separate reaction using 30.5 µl sterile distilled 
water, 5 µl 10X buffer, 5 µl MgCl2, 4 µl dNTPs, 2.5 µl of the 5’ primer and 2.5 µl of the 
3’ primer and 0.5 µl Taq polymerase per reaction (Lucigen Corp., USA).  Three to five 
colonies were isolated from the mupirocin plate and suspended into the 50 µl reaction.  
Reactions were run in thermal cycler using the settings: 95°C for 5 min., thirty-five 
cycles of 95°C for 30 sec., 57°C for 30 sec., and 72°C for 30 sec., then 72°C for 7 min., 
and then held at 4°C.  Negative controls used were water with no template DNA and a 
known mupirocin-sensitive, methicillin-susceptible S. aureus, ATCC strain 29213.  No 
positive controls were available; therefore, two different segments of the gene were 
chosen to identify the presence of ileS2.  The products were then run on a 2% agarose gel 
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for 2 hours at 70V, visualized with GelRed (Phenix Research, USA) and compared to a 
100 bp molecular weight marker (Invitrogen, USA).  
To determine the structural type of the plasmid carrying the ileS2 gene, PCR was 
run using the previously published primers: IS257F, ileS2-5’, ileS2-3’, and IS257R (Table 
3) in various combinations, under the conditions: 94°C for 5 min., thirty cycles of 94°C 
for 30 sec., 60°C for 40 sec., and 72°C for 60 sec., then 72°C for 10 min., and then held 
at 4°C (35).  PCR products from colony-PCR using the mupirocin-resistant strain, 
purified plasmid, and negative controls of colony PCR of ATCC strain 29213 and water 
with no template DNA were then run on 1% agarose gel at 80V for 90 min., visualized 
with GelRed and compared to the 1 kb Plus molecular weight marker (Invitrogen, USA).  
An additional PCR amplification was necessary to obtain an internal fragment of the 
upstream junction of ileS2, using novel primers ileS 518F and ileS 1186R (Table 3). 
PCR was performed to identify the native ileS gene using the primers ileS-F1 and 
ileS-R1 (30) (Table 3).  Conditions for thermal cycler were: 94°C for 5 min.; 30 cycles of 
94°C for 30 sec., 55°C for 30 sec., 72°C for 60 sec., then 72°C for 7 min., and held at 
4°C. 
 PCR products were purified using either the QIAprep Gel Purification kit 
(QIAgen, Valencia, CA) or the Zymoclean Gel DNA Recovery kit (Zymo Research; 
Irvine, CA) according to the manufacturers’ protocols.  Purified PCR products were then 
cloned into the pT7Blue plasmid vector using the Novagen pT7Blue Perfectly Blunt 
Cloning Kit (EMD Chemicals, Inc.; Darmstadt, Germany) following manufacturer’s 
protocol.  Resultant plasmids containing the upstream IS257-ileS2 junction, the 
downstream ileS2-IS257 junction and the fragment of the native ileS gene were submitted 
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to the Texas A&M Gene Technologies Lab for sequencing.  Resultant sequences were 
compared to sequences JX186508, JX186509, JX186511, JX186512,  JX186513, and 
JX186514  (30) and, HQ625435, HQ625436, HQ625437, and HQ625438 (35) in 




 Of the 572 isolates tested, only one isolate, 39-045, was resistant to mupirocin by 
testing on mupirocin agar (Fig. 1).  Isolate 39-045 was originally cultured from the nares 
of a healthy, one-year-old, castrated, male, Bernese mountain dog presenting to the Texas 
A&M College of Veterinary Medicine for an orthopedic evaluation.  This isolate was 
pan-susceptible to all antimicrobials tested using the COMPAN2F drug panel and 
negative for the presence of the mecA gene via PCR analysis.  Of the 175 isolates 
collected from healthy dogs that presented for elective orthopedic procedures, the 
prevalence of mupirocin resistance was 1 in 126 dogs or 0. 8%.  During this study, 195 S. 
pseudintermedius isolates were collected from 162 dogs and 3 cats with clinical 
infections resulting in a total of 370 S. pseudintermedius isolates from 288 dogs from 
September 22, 2010 and February 8, 2012 with an overall prevalence of 1 in 288 (0.3%).  
The prevalence of mupirocin-resistant S. pseudintermedius from the historical collection 
of 202 isolates from 159 dogs and 6 cats was 0 out of 159 dogs.   
 Upon PCR analysis using primers mupA and mupB, isolate 39-045 contained a 
fragment between 300 and 400 bp (Fig. 2).  Similarly, PCR analysis with M1 and M2 
primers revealed a band between 200 and 300 bp (Fig 2). 
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 Next, isolate 39-045 was evaluated using PCR for the IS257-ileS2 junctions using 
primers ileS2-5’, IS257F, ileS2-3’, and IS257R.  Isolate 39-045 contained a band between 
1650 and 2000 bp for primers ileS2-5’ and IS257R and a band between 1000 and 1650 bp 
for primers ileS2-3’ and IS257F (Fig. 3).  These bands were then sequenced and compared 
to previously published sequences.  Sequence analysis, using NCBI BLAST analysis, 
indicated a 100% similarity between isolate 39-045 and the previously published ileS2 
sequences from S. pseudintermedius JX186508 and a 97% similarity between 39-045 and 
JX186509 (30)  and a 99% similarity between isolate 39-045 and the previously 
published  sequence from S. aureus structural group S2 ileS2 plasmid HQ625436 (35).
 PCR analysis for the ileS gene was performed using the previously published 
primers ileS-F1 and ileS-R1 (30).  PCR analysis revealed a band between 850 and 1000 
bp (Fig. 4).  This fragment was also sequenced and compared to previously published 
sequences using MEGA5.1 software.  NCBI BLAST analysis indicated a 99% similarity 
between isolate 39-045 and the previously published sequences of the S. 
pseudintermedius chromosomal ileS gene: JX186511, JX186512, JX186513, JX186514 
(30).  Using MEGA5.1 software, three point mutations were identified between the native 
ileS of isolate 39-045 and that of S. pseudintermedius ED99 (NC_017568) (53) from T to 
C in our sequence at position 2082, T to C at 2097, and G to A at 2121.  Similarly, 
compared to the Matanovic sequence JX186511, there were four point mutations: From T 
to C mutation in our sequence at position 1413, A to G at 2076, T to C at 2082 and G to 







Screening of the 572 S. pseudintermedius isolates for low-level mupirocin 
resistance revealed that only one isolate was resistant to mupirocin.  Following 
phenotypic testing for low-level resistance, the isolate was analyzed for the presence of 
high-level mupirocin resistance by PCR amplification of two different regions of the 
plasmid-borne ileS2 gene.  The presence of bands at approximately 458-bp with mupA 
and mupB primers and approximately 237-bp with M1 and M2 primers indicate that 
isolate 39-045 contains the ileS2 gene (Fig. 2).  To further determine structural type of 
the plasmid, PCR for the IS257-ileS2 spacer regions was performed following a 
previously published molecular classification system (35).  The fragments are consistent 
with the amplification for structural group S2 ileS2 plasmids found in S. aureus, pattern 
II, with bands sized 1127-bp for primers ileS2-3’ & IS257F and at 1816-bp for primers 
IS257R & ileS2-5’(Figure 3).   
Previous work with the IS257-ileS2 junctions has been done with S. aureus (35, 
52) and in Staphylococcus haemolyticus (11).  Recently, plasmid-borne ileS2 was 
identified in S. pseudintermedius isolated from a dog with pyoderma in Croatia (30).  
Sequence analysis indicated a 100% similarity between isolate 39-045 and the previously 
published ileS2 sequences from S. pseudintermedius, JX186508 and a 97% similarity 
between 39-045 and JX186509 (30) and a 99% similarity between isolate 39-045 and the 
previously published  sequence from S. aureus structural group S2 ileS2 plasmid 
HQ625436 (35), supporting the concept that S. aureus and S. pseudintermedius share 
similar plasmids.  
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To determine whether isolate 39-045 carried a concurrent ileS mutation, PCR 
amplification of the chromosomal ileS gene was also performed using previously 
published primers ileS-F1 and ileS-R1 (30) (Fig 4).  The resultant 956 bp product was 
sequenced and analyzed using MEGA5.1 software, and analysis indicated a 99% 
similarity between isolate 39-045 and the previously published sequences of the S. 
pseudintermedius chromosomal ileS gene: JX186511, JX186512, JX186513, JX186514 
(30).  There were three point mutations from the native ileS of S. pseudintermedius ED99 
(NC_017568) from T to C in our sequence at position 2082, T to C at 2097, and G to A at 
2121.  Likewise, compared to the Matanovic sequence JX186511, there were four point 
mutations: From T to C mutation in our sequence at position 1413, A to G at 2076, T to C 
at 2082 and G to A at 2121.  All point mutations were silent, causing no change in the 
amino acid sequence.  
In summary, we found that the prevalence of mupirocin resistance was 0.8% 
(1/126) in healthy dogs without active, clinical staphylococcal infections.  While no 
mupirocin resistant isolates were found in our collection of isolates from dogs with 
clinical disease, the presence of plasmid-mediated mupirocin resistance is of concern as 
previous work has demonstrated that mupirocin resistance can be transmitted from one 
species of Staphylococcus to another in vivo (20).  Increased rates of methicillin-
resistance and multi-drug resistance in S. pseudintermedius and approval of mupirocin for 
use in dogs have made mupirocin an attractive alternative for topical use in canine 
pyoderma (48).  This could result in increased mupirocin-resistance in S. 
pseudintermedius over time.  With 36.5 percent of U.S. households owning a dog in 2012 
(3), there is a great potential for transmission of mupirocin resistance from canine isolates 
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of S. pseudintermedius to human isolates of S. aureus or vice versa.  This could have 
significant public health implications.  For these reasons, mupirocin resistance should be 
monitored and mupirocin use should be thoroughly considered before prescribing to 




CHAPTER III  
DISCUSSION AND CONCLUSION 
 
In this study, 572 samples of S. pseudintermedius, isolated from patients, mostly 
dogs, of the Texas A&M University College of Veterinary Medicine veterinary hospital, 
were analyzed for their susceptibility to mupirocin.  Of the 572 isolates, only one was 
phenotypically resistant to a low-level of mupirocin (8 µg/ml).  Subsequently, this isolate 
was analyzed by PCR and sequence analysis to determine whether it contained mutations 
in the chromosomal ileS gene or carried the high-level mupirocin resistance gene, ileS2 
on a plasmid.  PCR testing with primers that target ileS2 demonstrated the presence of 
bands at approximately 458 bp with primers mupA and mupB and at around 237 bp with 
primers M1 and M2, indicating the isolate contains the ileS2 gene.  Fifteen structural 
plasmid types have been identified in S. aureus based on orientation and position of the 
IS257-ileS2 spacer regions (35).  At the time that we initiated this investigation, there 
were no published accounts of the plasmid structure of mupirocin resistance plasmids in 
S. pseudintermedius; therefore, to further determine structural type of the plasmid, the 
PCR for the S. aureus IS257-ileS2 junctions was performed.  The fragments are 
consistent with amplification pattern II, with bands at 1127 bp for primers ileS2-3’ and 
IS257F and at 1816 bp for primers IS257R & ileS2-5’, which is consistent with structural 
group S2 ileS2 plasmids.  Previous work with the IS257-ileS2 junctions has been done 
with S. aureus (35, 52) and in Staphylococcus haemolyticus (11).  Subsequent to our 
study, the structure of a mupirocin resistance plasmid from S. pseudintermedius from 
Croatia was published in December 2012 (30) .  That study, as well as our investigation, 
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confirms the same pattern of IS257-ileS2 junction for S2 plasmids in S. pseudintermedius 
as in S. aureus.  This information, combined with the knowledge that staphylococci are 
able to transfer plasmids via conjugation from one species to another, indicates that 
mupirocin resistance is capable of being transferred from the dog-colonizing S. 
pseudintermedius to the human-colonizing S. aureus and vice versa.  While we found that 
mupirocin resistance was uncommon in our patient population the mupirocin-resistant 
isolate that we found came from a healthy dog that would not have been routinely tested.  
This could indicate that mupirocin resistance occurs more often than our study would 
suggest.  With 36.5 percent of U.S. households owning a dog in 2012 (3), there is a great 
potential for transmission of mupirocin resistance from animal strains of staphylococci to 
human strains or vice versa.  In the recent paper describing the mupirocin-resistant S. 
pseudintermedius isolate in Croatia, the owner of the colonized dog was a nurse.  We did 
not ask pet owners any questions with regard to the health of human family members so it 
is not possible to determine the origin of the mupirocin-resistance plasmid in our isolate.  
With recent increases in multi-drug resistance in both S. aureus and S. pseudintermedius 
(48), mupirocin has been increasingly used to treat resistant forms of both bacteria.  For 
these reasons, mupirocin resistance should be monitored and clinical use of mupirocin 
must be fully justified before prescribing.  
Antimicrobial therapy should be carefully considered in any situation, but 
especially in cases where multi-drug resistance is likely to occur.  In treatment of dogs, 
bacterial culture and susceptibility testing should be implemented when infections fail to 
respond to empiric therapy, clinical lesions are consistent with deep pyoderma, there is 
cytological evidence of a mixed infection, the dog’s condition relapses, there has been 
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recent antimicrobial administration for any reason, or if the dog has been diagnosed with 
MRSP previously (6).  In lieu of antimicrobial therapy for treatment of MRSP, topical 
use of chlorhexidine- or iodine-containing products to decontaminate the skin and coat 
and cleaning/disinfection of surfaces within the dog’s home may be viable alternative 
measures for the treatment  of MRSP infections in dogs (48).  Valentine et al. validated 
these findings in their study, showing that the clinical concentrations of chlorhexidine 
used to treat pyoderma are over 3000 times higher than the MIC for both MSSP and 
MRSP  (46).  Other therapy options include shampoos or leave-in conditioners containing 
10% ethyl lactate or 2.5-3% benzoyl peroxide with potentiating ingredients such as 
chitosan, liposomes, or lipid barriers that enhance contact time or penetration, depending 
on polarization of the active ingredient and the charge of the potentiating agent (21).  
Frequently, combinations of therapies work best.  Considerations when choosing topical 
treatment of pyoderma include location/extent of the infection, hair coat involvement, 
antibiotic therapy and its means of delivery, and the owner’s ability/willingness to 
comply (21).  
Staphylococci are capable of transferring antimicrobial resistance from one 
species to another.  Furthermore, conjugative mupirocin resistance plasmids are able to 
transfer between coagulase-negative and coagulase-positive staphylococci (32).  In a 
report by Hurdle et al., a patient in a nursing home undergoing mupirocin treatment for 
persistent MRSA carriage acquired high-level mupirocin resistance through conjugative 
transfer from a mupirocin-resistant strain of S. epidermidis (20).  These data support the 
concept that S. pseudintermedius may serve as a reservoir for mupirocin resistance for S. 
aureus, including MRSA. 
 28 
 
In conclusion our results show that although mupirocin resistance is not common 
in S. pseudintermedius isolates from animals in Texas, it does occur.  This is in keeping 
with similar studies (28, 30, 36, 46), but the fact that the mupirocin-resistant isolate was 
cultured from a healthy dog could indicate a higher prevalence in the general population 
than reported here.  Previous studies have demonstrated that mupirocin resistance can be 
transmitted from one species of Staphylococcus to another through conjugation.  Our 
results show a high degree of similarity between mupirocin resistance plasmids from S. 
pseudintermedius and S. aureus.  This reinforces the notion that S. pseudintermedius can 
serve as a reservoir for mupirocin resistance for S. aureus and vice versa.  Therefore, 
mupirocin resistance should be monitored and careful consideration should be employed 
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FIG. 1.  Mueller-Hinton agar plates demonstrating bacterial growth. Plate (A) 
supplemented with 8 μg/mL mupirocin  shows growth of only isolate 39-045 and the 
positive control, P. aeruginosa; and, an un-supplemented MH agar plate (B), 
demonstrates growth of all isolates with the exception of the isolate at position D2 within 
the deep well plate. This isolate was restruck on both a mupirocin agar plate and a control 








FIG. 2.  Presence of ileS2 in Staphylococcus pseudintermedius from a dog.  Agarose gel 
electrophoresis patterns showing PCR amplification products for ileS2 using primers 
mupA and mupB and primers M1 and M2. MWM indicates 100 bp molecular weight 
marker, 39-045 indicates methicillin-susceptible, mupirocin-resistant S. pseudintermedius 
isolate from a canine patient, 29213 indicates the methicillin-susceptible, mupirocin-
susceptible, S. aureus ATCC  29213 used as a negative control, and H2O indicates water 








FIG. 3.  Agarose gel electrophoresis patterns of products from PCR amplification of the 
IS257-ileS2 junctions of isolate 39-045.  Primer pairs for each reaction were as follows: 
PCR 1 - ileS2-5’ and IS257F; PCR 2 - ileS2-5’ and IS257R; PCR 3 - ileS2-3’ and IS257F; 
and PCR 4 - ileS2-3’ and IS257R.  MWM indicates 1 kb molecular weight marker, 39-045 
indicates methicillin-susceptible, mupirocin-resistant S. pseudintermedius isolate, 29213 
indicates the methicillin-susceptible, mupirocin-susceptible S. aureus ATCC 29213 used 
as a negative control, and H2O indicates water with no template DNA, also used as a 




FIG. 4.  Agarose gel electrophoresis patterns showing PCR amplification products for the 
native ileS gene using primers ileS-F1 and ileS-R1. MWM indicates 1 kb Plus molecular 
weight marker, 39-045 indicates methicillin-susceptible, mupirocin-resistant S. 
pseudintermedius isolate, 29213 indicates the methicillin-susceptible, mupirocin-
susceptible S. aureus ATCC 29213used as a positive control, and H2O indicates water 












TABLE 1.  Classification of isolates by study 
Study Isolates MRSP* MSSP** Dogs Cats 
Historic Clinical Data 202 75 127 159 6 
Clinical Infections†   
(Sep. 2010-Feb. 2012) 195 58 137 162 3 
Prevalence Study†† 
(Sep. 2010-Feb. 2012) 
175 13 162 126 0 
Totals 
572 146 426 447 9 
 
*MRSP = Methicillin-resistant S. pseudintermedius 
**MSSP = Methicillin-susceptible S. pseudintermedius 
†Isolates collected from patients with clinical infections concurrent with the period of the MRSP  
prevalence study conducted in patients presented for elective orthopedic procedures. 











TABLE 2.  Number of Staphylococcus pseudintermedius clinical infection isolates by 
collection site 
 





          Bone 
          Surgical Device 






          Urine 
          Bladder Mucosa 
          Bladder Stone 







          Frontal Sinus 
          Larynx 
          Lung 
          Pharynx 
          ET Tube 
          Bronchial 










          Penis 
          Prepuce 
          Vagina 







          Abscess 
          Blood 
          Eye 
          Joint Fluid 
          Nasal 
          Liver 
          Other 
          Perianal 
          Peritoneal Cavity 


















TABLE 3. Primers used in this study 
Target Gene Primer Sequence (From 5’ to 3’) Reference  
ileS2 
mupA  TATATTATGCGATGGAAGGTTGG   (2) 
mupB  AATAAAATCAGCTGGAAAGTGTTG  (2) 
M1  GTTTATCTTCTGATGCTGAG   (25) 
M2  CCCCAGTTACACCGATATAA   (25) 
IS257-ileS2 Junctions 
ileS2-5’  CCATGTCAACCCAGTATCC (35) 
IS257
F
  GGCATGGCGAAAATCCGTAG (35) 
ileS2-3’ TCGGTGTAACTGGGGAATTA  (35) 
IS257
R
 TGGCGTATTGATGAGACGTACATC (35) 
Internal Fragment of 
ileS2 Upstream 
Junction  
ileS 581F GGAGAGAGCAATAATGAATCGGC This Study 
ileS 1186R CTTGAAAGGTCTTTGCTATATTCGT This Study 
ileS 
ileS-F1  CGTGACCGTGGCGAATGGGT (30) 
ileS-R1  GTATGCGGAATGATTGGCG (30) 
 
 
 
 
 
 
 
 
 
